検索
Maze Therapeutics Inc
MAZEウォッチリストに追加
26.260USD
-0.700-2.60%
取引時間 （ET）15分遅れの株価
1.30B時価総額
損失額直近12ヶ月PER
詳細情報 Maze Therapeutics Inc 企業名
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
Maze Therapeutics Incの企業情報
企業コードMAZE
会社名Maze Therapeutics Inc
上場日Jan 31, 2025
最高経営責任者「CEO」Coloma (Jason V)
従業員数125
証券種類Ordinary Share
決算期末Jan 31
本社所在地171 Oyster Point Boulevard, Suite 300
都市SOUTH SAN FRANCISCO
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号94080
電話番号16508505070
ウェブサイトhttps://www.mazetx.com/
企業コードMAZE
上場日Jan 31, 2025
最高経営責任者「CEO」Coloma (Jason V)
Maze Therapeutics Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
23.25K
+61.54%
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Co-Founder, Director
Co-Founder, Director
--
--
Dr. Jason V. Coloma, Ph.D.
Dr. Jason V. Coloma, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Harold Bernstein, M.D., Ph.D.
Dr. Harold Bernstein, M.D., Ph.D.
President - Research and Development, Chief Medical Officer
President - Research and Development, Chief Medical Officer
--
--
Ms. Courtney J. Phillips
Ms. Courtney J. Phillips
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Dr. Nancy C. Andrews, M.D., Ph.D.
Dr. Nancy C. Andrews, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Jamie Brush, M.D.
Dr. Jamie Brush, M.D.
Independent Director
Independent Director
--
--
Mr. Alan B. Colowick, M.D.
Mr. Alan B. Colowick, M.D.
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
23.25K
+61.54%
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Co-Founder, Director
Co-Founder, Director
--
--
Dr. Jason V. Coloma, Ph.D.
Dr. Jason V. Coloma, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Harold Bernstein, M.D., Ph.D.
Dr. Harold Bernstein, M.D., Ph.D.
President - Research and Development, Chief Medical Officer
President - Research and Development, Chief Medical Officer
--
--
収益内訳
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2024
会社から関連データがまだ開示されていません。
地域別USD
会社名
収益
比率
United States
0.00
0.00%
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Sun, May 10
更新時刻: Sun, May 10
株主統計
種類
株主統計
株主統計
比率
Third Rock Ventures, LLC
9.80%
Frazier Life Sciences Management, L.P.
8.25%
Deep Track Capital LP
7.67%
ARCH Venture Partners
7.44%
Janus Henderson Investors
5.68%
他の
61.15%
株主統計
株主統計
比率
Third Rock Ventures, LLC
9.80%
Frazier Life Sciences Management, L.P.
8.25%
Deep Track Capital LP
7.67%
ARCH Venture Partners
7.44%
Janus Henderson Investors
5.68%
他の
61.15%
種類
株主統計
比率
Venture Capital
29.53%
Hedge Fund
22.51%
Investment Advisor/Hedge Fund
17.37%
Investment Advisor
14.65%
Private Equity
9.43%
Individual Investor
1.48%
Family Office
0.89%
Research Firm
0.69%
Bank and Trust
0.06%
他の
3.39%
機関投資家保有株
更新時刻: Wed, Apr 1
更新時刻: Wed, Apr 1
報告期間
機関投資家数
保有株式数
比率
変動額
2026Q1
213
53.41M
97.33%
+12.39M
2025Q4
156
40.80M
84.78%
+941.72K
2025Q3
111
39.53M
83.57%
-194.63K
2025Q2
100
42.58M
97.22%
+13.88M
2025Q1
93
44.69M
102.04%
+15.27M
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Third Rock Ventures, LLC
5.42M
10.91%
--
--
Dec 31, 2025
Frazier Life Sciences Management, L.P.
4.57M
9.19%
--
--
Dec 31, 2025
Deep Track Capital LP
4.25M
8.54%
+297.53K
+7.53%
Dec 31, 2025
ARCH Venture Partners
4.12M
8.29%
--
--
Dec 31, 2025
Janus Henderson Investors
3.14M
6.32%
+2.39M
+317.97%
Dec 31, 2025
Andreessen Horowitz
1.70M
3.42%
--
--
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
1.64M
3.31%
+439.68K
+36.53%
Dec 31, 2025
VR Adviser, LLC
1.55M
3.12%
+317.80K
+25.82%
Dec 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
Virtus LifeSci Biotech Clinical Trials ETF
1.64%
Invesco Dorsey Wright SmallCap Momentum ETF
0.53%
ALPS Medical Breakthroughs ETF
0.39%
iShares Micro-Cap ETF
0.12%
iShares Russell 2000 Value ETF
0.04%
ProShares UltraPro Russell2000
0.03%
ProShares Hedge Replication ETF
0.03%
iShares Russell 2000 ETF
0.02%
Proshares Ultra Russell 2000
0.02%
Schwab U.S. Small-Cap ETF
0.02%
詳細を見る
Virtus LifeSci Biotech Clinical Trials ETF
比率1.64%
Invesco Dorsey Wright SmallCap Momentum ETF
比率0.53%
ALPS Medical Breakthroughs ETF
比率0.39%
iShares Micro-Cap ETF
比率0.12%
iShares Russell 2000 Value ETF
比率0.04%
ProShares UltraPro Russell2000
比率0.03%
ProShares Hedge Replication ETF
比率0.03%
iShares Russell 2000 ETF
比率0.02%
Proshares Ultra Russell 2000
比率0.02%
Schwab U.S. Small-Cap ETF
比率0.02%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
